The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Editorial

The Ongoing Debate: Is There Actually a Causal Connection Between Anti-TNF&agr; Drugs and Skin Cancer?

Authors: Seçil Soylu MD, Ülker Gül MD

Abstract

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Cansu DU, Kasifoglu T, Açıkalın M, Korkmaz C. The development of primary cutaneous adenoid cystic carcinoma in a patient with ankylosing spondylitis treated with etanercept. South Med J 2009;102:738–740.CansuDU]]KasifogluT]]AçıkalınM]]KorkmazCThe development of primary cutaneous adenoid cystic carcinoma in a patient with ankylosing spondylitis treated with etanercept.South Med J2009102738-7402. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002;20(6 suppl 28):S152–S157.AntoniC]]BraunJSide effects of anti-TNF therapy: current knowledge.Clin Exp Rheumatol200220S152-S1573. Williams GM. Antitumor necrosis factor-&agr; therapy and potential cancer inhibition. Eur J Cancer Prev 2008;17:169–177.WilliamsGMAntitumor necrosis factor-&agr; therapy and potential cancer inhibition.Eur J Cancer Prev200817169-1774. Nair B, Raval G, Mehta P. TNF-&agr; inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022–1024.NairB]]RavalG]]MehtaPTNF-&agr; inhibitor etanercept and hematologic malignancies: report of a case and review of the literature.Am J Hematol2007821022-10245. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953–956.SmithKJ]]SkeltonHGRapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy.J Am Acad Dermatol200145953-9566. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate anti-tumor necrosis factor therapy in 18572 patients. Arthritis Rheum 2004;50:1740–1751.WolfeF]]MichaudKLymphoma in rheumatoid arthritis: the effect of methotrexate anti-tumor necrosis factor therapy in 18572 patients.Arthritis Rheum2004501740-17517. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699–703.GeborekP]]BladstromA]]TuressonC&etal;Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.Ann Rheum Dis200564699-7038. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414–1420.AsklingJ]]ForedCM]]BaecklundE&etal;Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.Ann Rheum Dis2005641414-14209. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–2285.BongartzT]]SuttonAJ]]SweetingMJ&etal;Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.JAMA20062952275-228510. Nakashima C, Tanioka M, Takahashi K, et al. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate. Clin Exp Dermatol 2008;33:437–439.NakashimaC]]TaniokaM]]TakahashiK&etal;Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate.Clin Exp Dermatol200833437-43911. Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol 2007;157:1076–1078.LyL]]CzarneckiDThe rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis.Br J Dermatol20071571076-107812. Sheppard J, Raza K, Buckley CD. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology 2007;46:1622–1623.SheppardJ]]RazaK]]BuckleyCDSkin cancer in psoriatic arthritis treated with anti-TNF therapy.Rheumatology2007461622-162313. Fryrear RS, Wiggins AK, Sangueza O, et al. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 2004;51:1026.FryrearRS]]WigginsAK]]SanguezaO&etal;Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy.J Am Acad Dermatol200451102614. Esser AC, Abril A, Fayne S, et al. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004;50(5 suppl):S75–S77.EsserAC]]AbrilA]]FayneS&etal;Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.J Am Acad Dermatol200450S75-S7715. Gül Ü, Kılıç A. Kaposi’s sarcoma in a patient with rheumatoid arthritis. Lep Mec 2007;38:34–38.GülÜ]]KılıçAKaposi’s sarcoma in a patient with rheumatoid arthritis.Lep Mec20073834-3816. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006;54(3 suppl 2):S92–S100.GottliebAB]]LeonardiCL]]GoffeBS&etal;Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.J Am Acad Dermatol200654S92-S10017. Gül U, Kiliç A, Dursun A. Carbamazepine-induced pseudo mycosis fungoides. Ann Pharmacother 2003;37:1441–1443.GülU]]KiliçA]]DursunACarbamazepine-induced pseudo mycosis fungoides.Ann Pharmacother2003371441-144318. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238–1244.MorelandLW]]CohenSB]]BaumgartnerSW&etal;Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.J Rheumatol2001281238-124419. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-&agr; antagonists. Br J Dermatol 2007;156:486–491.LeeHH]]SongIH]]FriedrichM&etal;Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-&agr; antagonists.Br J Dermatol2007156486-491